Disodium cromoglycate nasal spray in the treatment of perennial rhinitis.
In a double-blind crossover trial, 24 patients with perennial rhinitis have been treated with 2% disodium cromoglycate (DSCG) nasal spray. 15 patients preferred DSCG to placebo, 9 patients showed no preference. Analysis of the diary cards showed a significant preference of DSCG in the group which received placebo first for the symptoms blocking, secretion and sneezing (p less than 0.1), while no preference between the treatment periods occured in the group receiving DSCG first. A significantly higher IgG concentration in serum was found in 15 patients with preference for DSCG than with remainder (p less than 0.05). No other changes in immunoglobulin concentration in nasal secretion or serum were found, which could be related to the effect of DSCG. DSCG nasal spray is considered a valuable supplement in the treatment of perennial rhinitis.
D000336:Aerosols; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D010507:Periodicity; D012220:Rhinitis / Q000188:drug therapy* / Q000276:immunology; D012709:Serum Albumin / Q000032:analysis
D000336:Aerosols; D007136:Immunoglobulins; D012709:Serum Albumin; D004205:Cromolyn Sodium